Nanoparticle delivery of immunostimulatory agents for cancer immunotherapy

Summary

This review examines nanoparticle carriers for delivering agents that stimulate anticancer immunity, including adjuvants, cytokines, and monoclonal antibodies. These molecules can be potent but often perform poorly when administered directly because they are cleared unfavorably, degraded, or distributed without sufficient tumor or immune-cell specificity. The article synthesizes how encapsulation in biocompatible nanoparticles can protect such payloads and raise their bioavailability. It then focuses on biomimetic materials and surface modifications that add biological recognition or interaction functions beyond basic encapsulation, with the goal of improving delivery efficiency and the resulting immune response. The central conclusion is that carrier design can change the therapeutic behavior of immunostimulatory agents by coordinating protection, exposure, and targeting rather than merely increasing dose. Nature-inspired interfaces are presented as a way to further refine that control. The significance is a materials-based strategy for widening the usefulness of several distinct immunotherapy classes through a common delivery framework. As a review, it does not report a new treatment outcome, and the abstract provides no comparative ranking of carriers or payloads, no synthesis of clinical trial evidence, and no resolution of immune toxicity or manufacturing constraints.